Nature Communications (Apr 2023)
Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
- Wenjuan Dong,
- Jing Wang,
- Lei Tian,
- Jianying Zhang,
- Erik W. Settles,
- Chao Qin,
- Daniel R. Steinken-Kollath,
- Ashley N. Itogawa,
- Kimberly R. Celona,
- Jinhee Yi,
- Mitchell Bryant,
- Heather Mead,
- Sierra A. Jaramillo,
- Hongjia Lu,
- Aimin Li,
- Ross E. Zumwalt,
- Sanjeet Dadwal,
- Pinghui Feng,
- Weiming Yuan,
- Sean P. J. Whelan,
- Paul S. Keim,
- Bridget Marie Barker,
- Michael A. Caligiuri,
- Jianhua Yu
Affiliations
- Wenjuan Dong
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Jing Wang
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Lei Tian
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Jianying Zhang
- Department of Computational and Quantitative Medicine, City of Hope National Medical Center
- Erik W. Settles
- Pathogen and Microbiome Institute, Northern Arizona University
- Chao Qin
- Section of Infection and Immunity, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California
- Daniel R. Steinken-Kollath
- Pathogen and Microbiome Institute, Northern Arizona University
- Ashley N. Itogawa
- Pathogen and Microbiome Institute, Northern Arizona University
- Kimberly R. Celona
- Pathogen and Microbiome Institute, Northern Arizona University
- Jinhee Yi
- Pathogen and Microbiome Institute, Northern Arizona University
- Mitchell Bryant
- Pathogen and Microbiome Institute, Northern Arizona University
- Heather Mead
- Pathogen and Microbiome Institute, Northern Arizona University
- Sierra A. Jaramillo
- Pathogen and Microbiome Institute, Northern Arizona University
- Hongjia Lu
- Department of Molecular Microbiology and Immunology, Keck School of Medicine of University of Southern California
- Aimin Li
- Pathology Core of Shared Resources Core, Beckman Research Institute, City of Hope National Medical Center
- Ross E. Zumwalt
- Department of Pathology, University of New Mexico
- Sanjeet Dadwal
- Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center
- Pinghui Feng
- Section of Infection and Immunity, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California
- Weiming Yuan
- Department of Molecular Microbiology and Immunology, Keck School of Medicine of University of Southern California
- Sean P. J. Whelan
- Department of Molecular Microbiology, Washington University School of Medicine
- Paul S. Keim
- Pathogen and Microbiome Institute, Northern Arizona University
- Bridget Marie Barker
- Pathogen and Microbiome Institute, Northern Arizona University
- Michael A. Caligiuri
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Jianhua Yu
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- DOI
- https://doi.org/10.1038/s41467-023-37336-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
The serine protease factor Xa (FXa) is upregulated in COVID-19 patients and functions in the coagulation pathway. Here, Dong et al characterise the basis of its antiviral activity in the context of SARS-CoV-2 pandemic variants.
